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We observed bilateral pelvic foci of 18F-FDG uptake (BiPF) ex-
clusively in females—a finding not previously reported—and
assessed the frequency, anatomic localization, and clinical sig-
nificance of the uptake.Methods:On 18F-FDG PET/CT and cor-
egistered contrast-enhanced CT scans of 159 females (age,
16–81 y), the presence of BiPF and their location were evaluated.
The findings were correlated with the age and menstrual history
of the patient.Results:BiPFwere seen in 14 (22%) of 63 patients
up to53 yold, predominantly atmidmenstrual cycle, andwerebest
coregistered to the fallopian tubes on contrast-enhanced CT.
None of 96 patients older than 53 y showed BiPF. Conclusion:
Fallopian 18F-FDG uptake was seen predominantly in premeno-
pausal women at mid menstrual cycle. This finding is in accor-
dance with known cyclic changes of fallopian tubes in response
to ovarian hormones and may be the first, to our knowledge, im-
aging evidence revealing the influence of estrogen on the fallo-
pian tubes.
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An accumulation of 18F-FDG unrelated to malignancy
is frequently seen on PET (1–5). Such uptake may be
caused by normal variants or benign pathologic processes
or may be physiologic. PET/CT is indispensable for proper
interpretation of these benign findings for accurate staging
and patient management planning in oncology. For
example, without coregistered CT images, brown fat uptake
of 18F-FDG in atypical locations such as the retrocrural
region may be mistaken for adrenal metastasis (6).
In female patients, physiologic 18F-FDG uptake in the
ovary has been reported by several groups of investigators.
This finding is typically unilateral, focal, and discoid or
spheric and has been attributed to a functional follicle,
corpus luteum, or corpus luteal cyst (7–9). We recently
observed bilateral pelvic foci of 18F-FDG uptake (BiPF)
along the pelvic wall—1 on each side, exclusively in
female patients—on PET/CT studies. A search showed no
reports of this finding. Compared with the typical ovarian
uptake described in the literature, the observed findings
were always bilateral, often had a comma or tadpole or
tubular shape, and were always adjacent to the ovaries on
the coregistered PET/CT images. This retrospective study
was undertaken to assess the frequency, anatomic localiza-
tion, and possible clinical significance of this finding on
PET/CT.
MATERIALS AND METHODS
Patients
Our institutional review board approved the protocol for this
retrospective study. 18F-FDG PET/CT scans of 302 consecutive
patients were obtained between May 1, 2009, and May 31, 2009,
and reviewed. Of these patients, the 143 male patients were
excluded from this study. Of the remaining 159 female patients
(mean age, 52.3 y; age range, 16–81 y), 150 patients were referred
for evaluation of known malignancy and 9 patients for cancer
screening.
Of the 150 patients with known malignancy, 48 had gyneco-
logic and the remaining 102 patients had nongynecologic malig-
nancies. For those patients who showed BiPF, detailed information
on the indication for PET/CT, past medical history related to
pelvic surgery, and the menstrual cycle status including the first
day of the last normal menstrual period were obtained from the
patients’ medical records or PET/CT questionnaire.
Imaging Procedures
All patients fasted for at least 6 h before the administration of
18F-FDG and rested for an hour before undergoing PET/CT. Blood
glucose concentration was measured and confirmed to be less than
140 mg/dL. Approximately 5.5 MBq of 18F-FDG per kilogram of
body weight were injected intravenously. Imaging was performed
on a Biograph TruePoint 40 (Siemens Medical System). Sixty
minutes after 18F-FDG injection, a low-dose CT scan was
obtained for attenuation correction, with a 40-slice multidetector
helical CT unit (SOMATOM Sensation; Siemens), using the
following parameters: 120 kVp; 35 mA; 0.5-s rotation time; 1.2-mm
slice collimation; 40.3-mm feed per rotation; 3-mm scan re-
construction, with a reconstruction index of 2 mm; 50-cm field
of view; and 512 · 512 matrix. A PET scan was then immedi-
ately acquired from the level of the neck to the mid thigh in
3-dimensional mode at 3 min per bed position. The PET unit has
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an axial field of view of 21.6 cm and a spatial resolution of 4.0
mm in full width at half maximum at 1 cm from the center. PET
data were reconstructed iteratively using an ordered-subset ex-
pectation maximization algorithm with the low-dose CT datasets
for attenuation correction.
On completion of PET acquisition, a contrast-enhanced CT
scan of the same imaging field was immediately obtained at 120
kVp and 200 mA, with a collimation of 1.2 mm, after the
intravenous administration of 2.0 mL of contrast medium per
milligram (Omnipaque 300; GE Healthcare AS) injected at a rate
of 1.8–2.0 mL/s. Although low-dose CT was used for attenuation
correction, PET images were coregistered with enhanced CT
images obtained without moving the patient for optimal interpre-
tation of the study.
Image Interpretation and Analysis
For visual analysis, 2 experienced specialists certified in both
nuclear medicine and diagnostic radiology reviewed the PET/CT
scan. The exact location of BiPF on PET was determined on
coregistered enhanced CT images. For semiquantitative analysis,
regions of interest were drawn over these regions, and the
maximum standardized uptake value (SUVmax) of each region
was recorded. Finally, the findings were assessed in correlation
with menstrual status.
RESULTS
Frequency of BiPF According to Patient’s Age
Of the 159 women included in this study, 14 (8.8%)
showed BiPF. BiPF were seen in 1 of the 2 patients (50%)
in their late teens, 2 of the 6 patients (33%) in their
twenties, 4 of the 14 patients (29%) in their thirties, 5 of the
39 patients (13%) in their forties, 2 of the 55 patients (4%)
in their fifties, and in none of the 43 patients older than 60.
The mean and median ages of the 14 patients were 39 and
40 y, respectively. The youngest and oldest patients
showing BiPF were 17 and 53 y, respectively. The mean
SUVmax was 3.7 6 0.8 (range, 2.6–5.3) on the right and
3.5 6 0.8 (range, 2.5–4.9) on the left.
BiPF in Relation to Menstrual Status
Of the 14 patients with BiPF, 9 were regularly menstru-
ating, 3 presented with abnormal uterine bleeding, 1 was
close to menopause, and 1 did not menstruate because of
previous total abdominal hysterectomy (Table 1). The 9
patients with regular menstruation were in the ovulatory or
periovulatory phase, ranging from 10 to 18 d.
Anatomic Localization of BiPF on Enhanced CT
When 18F-FDG PET images were coregistered with
enhanced CT images, all 28 (14 bilateral) foci were
localized adjacent to the ovaries. None of the 28 was
associated with tumor. The appearance was usually tubular,
comma-shaped, or tadpole-shaped on at least 1 of the 4
views—that is, projection and 3 orthogonal views (Figs.
1–3). The findings in 2 patients were especially noteworthy.
In 1 patient, 18F-FDG PET showed 3 foci of increased
uptake—that is, BiPF and an additional third focus of
nodular uptake just below the left one of the BiPF (Fig. 2).
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On the enhanced CT scan, the BiPF were best coregistered
to the bilateral fallopian tubes, and the third focus corre-
sponded to a corpus luteum of the left ovary. The other
patient previously had a left oophorectomy because of
a benign mucinous ovarian tumor. BiPF were also seen in
this patient (Fig. 3). The findings in these 2 patients exclude
the possibility of bilateral ovarian 18F-FDG uptake.
Of the 14 patients with BiPF, 6 were evaluated for
nongynecologic malignancy, 6 for gynecologic malignancy
(4 uterine cervix cancer, 1 endometrial cancer, and 1
ovarian cancer), and 2 for cancer screening. Of the 6
patients with gynecologic malignancy, 4 were operated on
for the management of their malignancy, and no pathologic
condition was found in the fallopian tubes.
DISCUSSION
Focal, nonmalignant 18F-FDG uptake noted within the
female pelvis includes physiologic uptake in the bowel,
endometrium, and ovary. The CT portion of the PET/CT
study can be useful in localizing and characterizing foci of
increased 18F-FDG accumulation within the bowel (5).
Endometrial 18F-FDG uptake seems to be dependent on
the menstrual cycle (7). In premenopausal women, in-
creased 18F-FDG uptake was seen during the ovulatory
and menstrual phases in the normal cyclic endometrium. In
addition to the endometrium, the ovary is known to show
physiologic 18F-FDG uptake around the ovulatory and early
luteal phases in premenopausal women (7–9). Increased
18F-FDG uptake in the corpus luteal cyst is also well known
(10). Other than the endometrium and ovary, no female
reproductive organs have been reported in the literature to
show physiologically increased 18F-FDG uptake that is high
enough to be of concern. We identified increased 18F-FDG
uptake in the fallopian tubes on PET/CT with intravenous
contrast in a considerable proportion of female patients
(14/159 [8.8%]).
Although integrated PET/CT has significantly reduced
false-positive results related to physiologic or other benign
uptake, the precise localization of an 18F-FDG–avid focus
on CT without intravenous contrast is still challenging in
the interfaces of complex soft-tissue structures with similar
CT attenuation coefficients such as the female pelvis. In the
present study, the use of contrast enhancement facilitated
FIGURE 1. Case example showing typical appearance of
BiPF on PET, which are best localized to fallopian tubes on
coregistered enhanced CT scan. Projection images of PET/
CT show curvilinear, increased 18F-FDG uptake in right
pelvis (short arrow) and comma- or tadpole-shaped focus on
left (long arrow). Left focus appears more tubular on axial
coregistered image.
FIGURE 2. Patient with corpus luteum. Projection images
show 3 foci of nodular uptake, 1 on right and 2 on left. On
coregistered PET/CT images, shape of left lower focus is still
oval (long dotted arrow) and corresponds to corpus luteum
of left ovary. However, right focus (short arrow) and left
focus (long solid arrow) just above left ovary are tubular and
correspond to right and left fallopian tubes, respectively, on
each side of pelvic wall.
FIGURE 3. Patient with history of left oophorectomy. In
addition to increased uptake in right fallopian tube (short
arrow), increased tubular 18F-FDG uptake corresponding to
left fallopian tube (long arrow) along left pelvic side wall is
clearly evident.
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the identification of the ovary, thus helping us with accurate
localization of BiPF in relation to the ovaries on PET/CT.
BiPF in all 14 patients were found adjacent to but clearly
not in the ovaries.
In addition to anatomic localization on the coregistered
enhanced CT images, there are several other reasons and
other evidence supporting the theory that BiPF do not
represent ovarian uptake. Ovarian uptake of 18F-FDG was
attributed previously to the dominant follicle or corpus
luteum or corpus luteal cyst (7–9). Naturally, the ovarian
uptake should be unilateral. In contrast, our finding is
bilateral. Moreover, this finding was noted in a patient
whose left ovary was surgically removed. In another patient
with a corpus luteum of the left ovary, BiPF were seen in
addition to the nodular 18F-FDG uptake corresponding to
the corpus luteum. Although CT is somewhat limited in
defining the precise structures of the fallopian tube in some
patients, the findings in these 2 patients together with other
factors mentioned—that is, location on the enhanced CT
scan and bilateral nature in all 14 patients—effectively
exclude the ovary as a possible cause of BiPF.
As with endometrial and ovarian uptake, 18F-FDG
uptake in the fallopian tubes was also seen mostly in
patients of active reproductive age, and the oldest patient
showing this finding was 53 y old. Of the 14 patients with
BiPF, 9 were regularly menstruating, with their menstrual
cycles being in the ovulatory or periovulatory phase.
Menstrual cycle day could not be accurately determined
in 4 of the 14 patients: 3 patients had abnormal uterine
bleeding and 1 was close to menopause. The remaining one
33-y-old patient had undergone total abdominal hysterec-
tomy without oophorectomy because of early uterine cervix
cancer. The correlation of BiPF with menstrual cycle
history raises the possibility of a relationship between
ovarian hormones and BiPF in women with intact ovarian
function.
The fallopian tubes undergo cyclic changes under the
influence of ovarian hormones (11). Cells in the fallopian
tubes increase in height during the proliferative phase and
reach maximal height in the ovulatory or periovulatory
period. Of the ovarian hormones, the maximal level of
estrogen at mid cycle stimulates cellular hypertrophy,
secretion, and ciliogenesis, whereas a high level of pro-
gesterone is associated with cellular atrophy and deciliation
(12). It seems quite likely that BiPF identified in this study
represents the physiologic metabolic response of the
fallopian tubes to the high level of estrogen at mid cycle.
It is conceivable that 18F-FDG PET may have a role in the
functional assessment of the fallopian tubes.
CONCLUSION
We identified physiologic 18F-FDG uptake in the fallo-
pian tubes. The finding was seen predominantly in pre-
menopausal women at mid menstrual cycle. This is
certainly in accordance with known cyclic changes of
fallopian tubes in response to ovarian hormones and may
be the first imaging evidence revealing the influence of
estrogen on the fallopian tubes.
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